Lamotrigine — Lamictal — is the mood stabilizer for the depressive pole of bipolar disorder. Where lithium and valproate are best characterized as antimanic agents that have mood-stabilizing maintenance effects, lamotrigine is best characterized as bipolar depression prophylaxis. It reduces depressive episode frequency more than manic episode frequency, and for bipolar II patients in particular — where the depressive pole dominates the lifetime burden — lamotrigine is often the maintenance agent of choice.
- Class
- Anticonvulsant mood stabilizer (sodium channel blocker)
- Mechanism
- Voltage-gated sodium channel blockade → reduced glutamate release. Modulator of glutamatergic transmission.
- Typical dose
- Slow titration mandatory: 25 mg/day weeks 1-2, 50 mg weeks 3-4, 100 mg week 5, 200 mg week 6. Target 200-400 mg/day.
- Half-life
- ~25-33 hours (shortened to ~14 hours with enzyme inducers like carbamazepine; roughly doubled to ~48-70 hours with valproate)
- FDA indications
- Bipolar I maintenance (particularly bipolar depression prophylaxis), epilepsy. Not effective for acute mania.
- Key adverse effects
- Headache, dizziness, nausea, blurred vision, ataxia. Rash (benign or Stevens-Johnson syndrome — discontinue any rash).
Black box: Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, especially with rapid titration or interaction with valproate (which doubles lamotrigine levels — halve the dose)
Slow titration is non-negotiable to reduce rash risk. With valproate, halve the lamotrigine dose. Excellent tolerability profile (no weight gain, no cognitive effects, no metabolic burden) makes it preferred for bipolar depression prophylaxis. Not for acute mania.
The mechanism is voltage-gated sodium channel blockade, which reduces glutamate release. It is conceptually similar to several other anticonvulsants, but the clinical mood-stabilizing profile is distinctive.
Lamotrigine is the mood stabilizer for the depressive pole — effective for bipolar maintenance and depression prevention, defined clinically by the rash risk that dictates its titration.
Mechanism note: Lamotrigine's clinical identity is bipolar-depression maintenance with excellent tolerability — purchased at the cost of a slow, non-negotiable titration to avoid serious rash.
What makes lamotrigine attractive is the tolerability profile. No meaningful weight gain. No cognitive dulling. No metabolic burden. No sedation at typical doses. Many patients describe lamotrigine as the cleanest psychiatric medication they have been on. For long-term maintenance, that profile matters enormously.
The catch is the rash. Stevens-Johnson syndrome and toxic epidermal necrolysis can occur with lamotrigine, particularly during titration. The risk is highest in the first two to eight weeks and rises with rapid titration or with valproate co-administration. To mitigate this, lamotrigine has a mandatory slow titration schedule: 25 milligrams daily for weeks 1-2, 50 milligrams daily for weeks 3-4, 100 milligrams daily for week 5, 200 milligrams daily for week 6. With valproate co-administration, halve all doses. With enzyme-inducing co-administration (like carbamazepine), the target may need to be higher.
The slow titration is non-negotiable. Faster titration substantially increases rash risk. If the patient interrupts dosing for more than five days, the titration must restart from the beginning. Counsel every patient at the prescription: any rash during titration → stop the medication immediately and contact me. Most rashes are benign and not Stevens-Johnson — but distinguishing requires clinical evaluation, and the cost of being wrong is severe.
Lamotrigine is not effective for acute mania. The slow titration alone makes it impractical for acute use, and the mechanism doesn't deliver antimanic effect. The patient in a manic episode needs something faster — lithium, valproate, an antipsychotic — and lamotrigine is added later for maintenance once the acute episode resolves.
Lamotrigine pairs well with antimanic agents. Lithium plus lamotrigine is a thoughtful maintenance regimen for the bipolar patient with both poles — lithium covers mania prophylaxis and provides anti-suicidal effect; lamotrigine covers bipolar depression prophylaxis with excellent tolerability. For bipolar II, lamotrigine monotherapy maintenance is often sufficient.
- Cost
- Generic: ~$10-30/month. Starter kits available.
- Generic status
- Generic since 2008.
- Formulary typical
- Tier 1-2 generic.
- Access friction
- Slow titration is the prescribing reality — patient and prescriber both need to commit to weeks of careful escalation. Starter dose packs (Lamictal Starter Kit) simplify titration but cost more than generic individual doses.
Prescriber tip: Counsel rash precautions explicitly at every titration step. With valproate co-administration, halve all doses. Don't let the patient interrupt and restart at full target dose.
Other side effects: headache, dizziness, nausea, blurred vision early in titration, occasional ataxia. All typically modest. The drug is well tolerated long-term in most patients, which is much of the reason it has the role it does.
For the patient whose bipolar disorder is dominated by depression, lamotrigine is the maintenance answer.